Dexamethasone Modifies Cystatin C-Based Diagnosis of Acute Kidney Injury During Cisplatin-Based Chemotherapy

Timothy J. Pianta, John W. Pickering, Lena Succar, Melvin Chin, Trent Davidson, Nicholas A. Buckley, Fahim Mohamed, Zoltan H. Endre
2017 Kidney & Blood Pressure Research  
Background/Aims: Plasma cystatin C (pCysC) may be superior to serum creatinine (sCr) as a after cisplatin-based chemotherapy is potentially affected by accompanying corticosteroid anti-emetic therapy and hydration. Methods: In a prospective observational study pCysC, cisplatin, or both, and in controls. Results: In patients, pCysC increases were greater than sCr 9 patients (35%) for pCysC compared with 2 (8%) for sCr (p = 0.04) and increases in sCr were accompanied by increased KIM-1 and
more » ... ed KIM-1 and clusterin excretion, but increases in pCysC alone were not. In rats, dexamethasone administration produced dose-dependent increases in pCysC (and augmented cisplatin-induced increases in pCysC), but did not augment histological Conclusions: In the presence of dexamethasone, elevation of pCysC does not reliably diagnose AKI after cisplatin-based chemotherapy.
doi:10.1159/000469715 pmid:28315878 fatcat:othph46knvgdnhxxjm75rt3ddy